These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 24721226)

  • 1. Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
    Whang JA; Chang BY
    Drug Discov Today; 2014 Aug; 19(8):1200-4. PubMed ID: 24721226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bruton's Tyrosine Kinase mediates platelet receptor-induced generation of microparticles: a potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints.
    Hsu J; Gu Y; Tan SL; Narula S; DeMartino JA; Liao C
    Immunol Lett; 2013 Feb; 150(1-2):97-104. PubMed ID: 23266841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents.
    Xu D; Kim Y; Postelnek J; Vu MD; Hu DQ; Liao C; Bradshaw M; Hsu J; Zhang J; Pashine A; Srinivasan D; Woods J; Levin A; O'Mahony A; Owens TD; Lou Y; Hill RJ; Narula S; DeMartino J; Fine JS
    J Pharmacol Exp Ther; 2012 Apr; 341(1):90-103. PubMed ID: 22228807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care.
    Gillooly KM; Pulicicchio C; Pattoli MA; Cheng L; Skala S; Heimrich EM; McIntyre KW; Taylor TL; Kukral DW; Dudhgaonkar S; Nagar J; Banas D; Watterson SH; Tino JA; Fura A; Burke JR
    PLoS One; 2017; 12(7):e0181782. PubMed ID: 28742141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amplification of IL-21 signalling pathway through Bruton's tyrosine kinase in human B cell activation.
    Wang SP; Iwata S; Nakayamada S; Niiro H; Jabbarzadeh-Tabrizi S; Kondo M; Kubo S; Yoshikawa M; Tanaka Y
    Rheumatology (Oxford); 2015 Aug; 54(8):1488-97. PubMed ID: 25724205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants.
    Hartkamp LM; Fine JS; van Es IE; Tang MW; Smith M; Woods J; Narula S; DeMartino J; Tak PP; Reedquist KA
    Ann Rheum Dis; 2015 Aug; 74(8):1603-11. PubMed ID: 24764451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bruton's tyrosine kinase is not essential for LPS-induced activation of human monocytes.
    Pérez de Diego R; López-Granados E; Pozo M; Rodríguez C; Sabina P; Ferreira A; Fontan G; García-Rodríguez MC; Alemany S
    J Allergy Clin Immunol; 2006 Jun; 117(6):1462-9. PubMed ID: 16751014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis.
    Park JK; Byun JY; Park JA; Kim YY; Lee YJ; Oh JI; Jang SY; Kim YH; Song YW; Son J; Suh KH; Lee YM; Lee EB
    Arthritis Res Ther; 2016 Apr; 18():91. PubMed ID: 27090981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bruton's tyrosine kinase is dispensable for the Toll-like receptor-mediated activation of mast cells.
    Zorn CN; Keck S; Hendriks RW; Leitges M; Freudenberg MA; Huber M
    Cell Signal; 2009 Jan; 21(1):79-86. PubMed ID: 18848985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
    He L; Pei H; Zhang C; Shao M; Li D; Tang M; Wang T; Chen X; Xiang M; Chen L
    Eur J Med Chem; 2018 Feb; 145():96-112. PubMed ID: 29324347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.
    MacPartlin M; Smith AM; Druker BJ; Honigberg LA; Deininger MW
    Leukemia; 2008 Jul; 22(7):1354-60. PubMed ID: 18548107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton's tyrosine kinase is activated upon CD40 stimulation in human B lymphocytes.
    Brunner C; Avots A; Kreth HW; Serfling E; Schuster V
    Immunobiology; 2002 Oct; 206(4):432-40. PubMed ID: 12437073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bruton's tyrosine kinase as a drug discovery target.
    Pan Z
    Drug News Perspect; 2008 Sep; 21(7):357-62. PubMed ID: 19259548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.
    Di Paolo JA; Huang T; Balazs M; Barbosa J; Barck KH; Bravo BJ; Carano RA; Darrow J; Davies DR; DeForge LE; Diehl L; Ferrando R; Gallion SL; Giannetti AM; Gribling P; Hurez V; Hymowitz SG; Jones R; Kropf JE; Lee WP; Maciejewski PM; Mitchell SA; Rong H; Staker BL; Whitney JA; Yeh S; Young WB; Yu C; Zhang J; Reif K; Currie KS
    Nat Chem Biol; 2011 Jan; 7(1):41-50. PubMed ID: 21113169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling.
    Bender AT; Gardberg A; Pereira A; Johnson T; Wu Y; Grenningloh R; Head J; Morandi F; Haselmayer P; Liu-Bujalski L
    Mol Pharmacol; 2017 Mar; 91(3):208-219. PubMed ID: 28062735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BTK Signaling in B Cell Differentiation and Autoimmunity.
    Corneth OBJ; Klein Wolterink RGJ; Hendriks RW
    Curr Top Microbiol Immunol; 2016; 393():67-105. PubMed ID: 26341110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approaching the active conformation of 1,3-diaminopyrimidine based covalent inhibitors of Bruton's tyrosine kinase for treatment of Rheumatoid arthritis.
    Huang Z; Zhang Q; Yan L; Zhong G; Zhang L; Tan X; Wang Y
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1954-7. PubMed ID: 26976214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of glomerulonephritis in lupus-prone NZB × NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase.
    Mina-Osorio P; LaStant J; Keirstead N; Whittard T; Ayala J; Stefanova S; Garrido R; Dimaano N; Hilton H; Giron M; Lau KY; Hang J; Postelnek J; Kim Y; Min S; Patel A; Woods J; Ramanujam M; DeMartino J; Narula S; Xu D
    Arthritis Rheum; 2013 Sep; 65(9):2380-91. PubMed ID: 23754328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Research Progress of BTK Inhibitors in the Treatment of Autoimmune Diseases.
    Lin P; Zhang D; Lin J
    Curr Top Med Chem; 2023; 23(28):2609-2620. PubMed ID: 37861005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.